CTOs on the Move

Nexstim

www.nexstim.com

 
Founded in Finland in 2000, Nexstim is the world leader in Navigated Brain Stimulation (NBS) with image-guided Transcranial Magnetic Stimulation (TMS). The company is committed to improving the quality of life of patients. Nexstim has pioneered the technology for brain diagnostics with the Navigated Brain Stimulation (NBS) System as the first and only FDA-cleared and CE-marked navigated TMS (nTMS) device for pre-surgical mapping of the motor and speech cortices. The advanced technology providing navigation to TMS has led NBS to be recognized as the emerging standard for pre-operative direct functional mapping. Nexstim initiated its two year multicenter clinical trial on ...
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.nexstim.com
  • 1360 Union Hill Road Suite 5B
    Alpharetta, GA USA 30004
  • Phone: 770.664.1000

Executives

Name Title Contact Details

Similar Companies

Cellnetix

Cellnetix is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Exagen Diagnostics

Exagen Diagnostics, Inc. is committed to providing excellent service to our physicians, patients and partners.

NitroMed, Inc.

NitroMed, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Arnold A Welu Dental Laboratory

Arnold A Welu Dental Laboratory is a Fargo, ND-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cerus

Cerus Corporation is dedicated solely to safeguarding the world`s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System for Cryoprecipitation is approved for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex), a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency.